|XDATA – October 23rd 2015|
|Arvinas Holding Company issued equity for a total of $41.61 million in a non-brokered investment round. The transaction which started a week ago, garnered the support of sixteen investors. No offering was previously initiated by the company under a registration exemption with the SEC.|
|Arvinas Holding Company develops novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to the company’s proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company is backed by Merck.|
|The company was registered in 2014 and has its headquarters located in New Haven CT. Arvinas Holding Company elected to keep its revenues undisclosed.
The executive team includes Manuel Litchman and Sean Cassidy.
The board of directors includes Andrew Levin, Brad Margus, Jonathan Soderstrom, Kush Parmar, Liam Ratcliffe, Stephen Squinto and Tim Shannon.
Company: Arvinas Holding Company
Amount offered: $41.61 million
Amount placed: $41.61 million
SEC filing: Source
First sale: 10-16-2015
Data as of: 10-23-2015
Hey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen.